---
title: "Bio Green Med Solution shareholders re-elect two directors at annual meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290417875.md"
description: "Bio Green Med Solution held its annual shareholder meeting on June 18, 2025. Shareholders re-elected Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj as directors for three-year terms expiring in 2029. Additionally, investors ratified SFAI Malaysia Plt. as the independent auditor for the fiscal year ending December 31, 2026."
datetime: "2026-06-22T10:11:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290417875.md)
  - [en](https://longbridge.com/en/news/290417875.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290417875.md)
---

# Bio Green Med Solution shareholders re-elect two directors at annual meeting

-   Bio Green Med Solution held its annual shareholder meeting on June 18, 2025. \* Shareholders elected two directors, Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj, for three-year terms expiring in 2029. \* Investors ratified SFAI Malaysia Plt. (PCAOB: 7167) as independent auditor for the fiscal year ending Dec. 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio Green Med Solution Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029452), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BGMS.US](https://longbridge.com/en/quote/BGMS.US.md)
- [BGMSP.US](https://longbridge.com/en/quote/BGMSP.US.md)

## Related News & Research

- [Bio Green Med Solution Q2 FY26 net loss narrows to $405,000; revenue rises to $336,000](https://longbridge.com/en/news/295704525.md)
- [Valion Bio agrees to sell 1,500 Series B preferred shares to 3i for $1.5 million in private placement](https://longbridge.com/en/news/296091036.md)
- [Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trial](https://longbridge.com/en/news/295935335.md)
- [OrbiMed Advisors acquires 1.940.000 Braveheart Bio common shares worth $ 34,92 juta](https://longbridge.com/en/news/295583346.md)
- [Belite Bio CEO Lin Yu-Hsin disposes of 365 shares worth $65,061.11](https://longbridge.com/en/news/295917602.md)